Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)

References

• World Health Assembly. Global eradication of poliomyelitis by the year 2000 (resolution 41.28); 1988 [cited 2019 Jun 4]. Available from: http://www.who.int/csr/ihr/polioresolution4128en.pdf
   Google Scholar
• Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Medscape J Med. 2008;10(8):190.
   PubMedGoogle Scholar
• World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1); 2008 [cited 2019 Jun 4]. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf
   Google Scholar
• Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - Worldwide, 2016. Morbidity Mortality Weekly Rep. 2016;65(35):934–938.
   PubMed Web of Science ®Google Scholar
• Global Polio Eradication Initiative. One step close to eradication: the withdrawal of type two oral polio vaccine complete; 2016 cited 2016 Jun 17. Available from: http://www.polioeradication.org/mediaroom/newsstories/One-Step-Close-to-Eradication-the-Withdrawal-of-Type-Two-Oral-Polio-Vaccine-Complete/tabid/526/news/1390/Default.aspx?popUp=true
   Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines. 2018;17(8):739–751.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Wassalik SGF, et al. An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infect Dis. 2015;15(389). DOI:10.1186/s12879-12015-11112-12878.
   Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential OPV cessation risk management strategy. Epidemiol Infect. 2017;145(2):217–226.
   PubMed Web of Science ®Google Scholar
• Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010;172(11):1213–1229.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, et al. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23(4):703–749.
   Google Scholar
• World Health Organization. Transmission of wild poliovirus type 2 - Apparent global interruption. Weekly Epidemiological Rec. 2001;76:95–97.
   PubMedGoogle Scholar
• Kew OM, Cochi SL, Jafari HS, et al. Possible eradication of wild poliovirus type 3–worldwide, 2012. Morbidity Mortality Weekly Rep. 2014;63(45):1031–1033.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Three years with no wild poliovirus type 3 - November 10, 2015; 2016 [cited 2016 Nov 28]. Available from: http://polioeradication.org/news-post/three-years-with-no-wild-poliovirus-type-3/
   Google Scholar
• Duintjer Tebbens RJ, Kalkowska DA, Wassilak SG, et al. The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis. 2014;14:45.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014;210(Suppl 1):S475–S484.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Kim J-H, et al. Review: oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. 2013;23(4):680–702.
   Google Scholar
• Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis. 2014;210(Suppl 1):S398–S411.
   PubMedGoogle Scholar
• Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis. 2014;210(Suppl 1):S412–S423.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infect Dis. 2015;15(376). DOI:10.1186/s12879-12015-11116-12874
   Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. J Infect Dis. 2017;216(Suppl 1):S168–S175.
   PubMedGoogle Scholar
• Thompson KM, Duintjer Tebbens RJ. Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. J Infect Dis. 2017;216(Suppl 1):S176–S182.
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC Infect Dis. 2016;16:237.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. BMC Infect Dis. 2016;16:231.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, et al. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. J Vaccines Vaccin. 2016;7(5):340.
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Hampton LM, Thompson KM. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. BMC Infect Dis. 2018;18:165.
   PubMed Web of Science ®Google Scholar
• World Health Organization and UNICEF. 17th WHO/UNICEF consultation with OPV/IPV manufacturers and national authorities for containment of polio vaccine producing countries; 2018 [cited 2019 Feb 21]. Available from: http://polioeradication.org/wp-content/uploads/2018/11/2018_WHO_UNICEF_Consultation_Mtg_Report_FINAL.pdf
   Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis. 2014;210(Suppl 1):S485–S497.
   PubMedGoogle Scholar
• Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of live polioviruses. Vaccine. 2015;33(3):1568–1577.
   PubMedGoogle Scholar
• Kalkowska DA, Duintjer Tebbens RJ, Grotto I, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2015;211(11):1800–1812.
   PubMed Web of Science ®Google Scholar
• World Health Organization. GAP III: WHO global action plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use; 2015 [cited 2015 Nov 9]. Available from: http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/GAPIII_2014.pdf.
   Google Scholar
• Bandyopadhyay AS, Garon J, Seib K, et al. Polio vaccination: past, present and future. Future Microbiol. 2015;10(5):791–808.
   PubMed Web of Science ®Google Scholar
• Van Damme P, De Coster I, Bandyopadhyay AS, et al. A blinded phase 1 study of the safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults. Lancet. 2019 [cited 2019 Jun 4]. DOI:10.1016/S0140-6736(19)31279-6
   Google Scholar
• World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2017 - conclusions and recommendations. Weekly Epidemiological Rec. 2017;92(22):301–320.
   PubMedGoogle Scholar
• Anis E, Kopel E, Singer S, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveillance. 2013;18(38):20586.
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, et al. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis. 2016;16:137.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. Expert Rev Vaccines. 2017;16(6):577–586.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for OPV cessation. Expert Rev Vaccines. 2012;11(4):449–459.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Expert Rev Vaccines. 2014;13(2):221–234.
   PubMed Web of Science ®Google Scholar
• World Health Organization GPEI. Polio eradication and endgame Strategic Plan (2019–2023); 2019 cited 2019 Jun 4. Available from: http://polioeradication.org/wp-content/uploads/2019/05/polio-endgame-strategy-2019-2023.pdf
   Google Scholar